74%
of retail investor accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
74%
of retail investor accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Allogene Therapeutics Inc
Open
SectorHealthcare
3.4 26.39
Overview
Share price change
24h
Min
2.69
Max
4.43
Income | 2.6M -39M |
|---|---|
Employees | 150 |
EBITDA | -1.4M -39M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +252.94% upside |
Next Earnings | 12 May 2026 |
|---|
Market Cap | 72M 634M |
|---|---|
Previous open | -22.99 |
Previous close | 3.4 |
News Sentiment
By Acuity
34%
66%
91 / 348 Healthcare
Technical Score
By Trading Central
Confidence
Very Strong Bearish Evidence
Allogene Therapeutics Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Allogene Therapeutics Inc Forecast
Price Target
By TipRanks
252.94% upside
12 Months Forecast
Average 9.6 USD 252.94%
High 14 USD
Low 7 USD
Based on 7 Wall Street analysts offering 12 month price targets forAllogene Therapeutics Inc - Dist in the last 3 months.
Sentiment
By Acuity
91 / 348 Healthcare
News Sentiment
Bullish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Allogene Therapeutics Inc
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Live chat